Clinical data | |
---|---|
Pronunciation | /juːˈkrɪsə/ yoo-KRIS-ə |
Trade names | Eucrisa, Staquis |
Other names | AN-2728 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617019 |
License data |
|
Pregnancy category |
|
Routes of administration | Topical (ointment) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.225.309 |
Chemical and physical data | |
Formula | C14H10BNO3 |
Molar mass | 251.05 g·mol−1 |
3D model (JSmol) | |
| |
|
Crisaborole, sold under the brand name Eucrisa among others, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in adults and children.[1][2][3][4]
The most common side effects are reactions at the application site (including burning or stinging).[3]
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known.[1][2]
Staquis EPAR
was invoked but never defined (see the help page).